Search results for: hospital

ACR on Air: New Rheumatology Podcast Introduced

Susan Bernstein | September 2, 2019

A new podcast from the ACR provides in-depth discussions about newly published science, regulatory updates, advocacy and volunteer opportunities for the rheumatology community…

FDA Approves Upadacitinib for RA

Michele B. Kaufman, PharmD, BCGP | September 2, 2019

Results from multiple phase 3 clinical trails have led to the FDA approval of upadacitinib to treat patients with moderate to severe active RA…

Intensive, Personalized Learning

Susan Bernstein | August 28, 2019

During the 2019 ACR/ARP Annual Meeting, the new Meet the Professor Workshops and sessions will feature hands-on training on state-of-the-art topics…

Filgotinib Promising for RA

Michele B. Kaufman, PharmD, BCGP | August 26, 2019

Research shows filgotinib may be safe and effective for treating rheumatoid arthritis. The drug’s manufacturer is expected to be submit a new drug application for filgotinib to the FDA in 2019…

Shingles Vaccine Not the Only Immunization Linked with Gout Flare

Marilynn Larkin | August 21, 2019

NEW YORK (Reuters Health)—The recombinant shingles vaccine (RZV) is associated with an increased risk of gout flare, and a new study suggests other vaccines may trigger flares as well, researchers say. “Our findings are novel because for the first time, we have identified a trigger for gout flares that presumably acts through [an inflammatory] pathway,…

Improved Pregnancy Outcomes for Women with SLE

Lara C. Pullen, PhD | August 19, 2019

Recent research indicates that previous concerns about mortality associated with pregnancy in women with SLE may no longer be applicable. In the study, researchers found a significant decline in the in-hospital maternal mortality rate of women with SLE and a decrease in their length of non-delivery related hospitalization over the past two decades…

Otilimab Begins Phase 3 Clinical Studies for RA

Michele B. Kaufman, PharmD, BCGP | August 19, 2019

In a four-part clinical trial program, researchers are assessing the safety and efficacy of otilimab with placebo in RA patients, along side conventional treatments, such as tofacitinib, and DMARDs…

Recent Awards & Appointments in Rheumatology

Gretchen Henkel | August 16, 2019

Prestigious Carol Nachman Prize for Research in Rheumatology Awarded to Ellen Gravallese On May 10, Ellen M. Gravallese, MD, the Myles J. McDonough Chair in Rheumatology and chief of the Division of Rheumatology at University of Massachusetts Medical School, Worcester, was awarded the prestigious Carol Nachman Prize for lifetime achievement in rheumatology research in Wiesbaden,…

Case Report: Not All Crystals Are Gout

Katherine Yates, MD, Erin H. Penn, MD, & Minna J. Kohler, MD | August 16, 2019

Patients with chronic kidney disease (CKD) often experience joint pain due to various etiologies, including crystalline arthropathies, renal osteodystrophy, amyloid arthropathy, erosive osteoarthritis, avascular necrosis and even erosive spondylarthrosis.1 Below, we present a case of crystalline arthropathy in a patient with chronic kidney disease, mistaken for gout. The Case A 29-year-old man was admitted to…

Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions

Nitasha Kumar, MD | August 16, 2019

Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…